Jane Street Group LLC Has $548,000 Stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Jane Street Group LLC increased its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) by 5,932.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,662,682 shares of the company's stock after acquiring an additional 1,635,119 shares during the period. Jane Street Group LLC owned about 88.96% of Tonix Pharmaceuticals worth $548,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock worth $650,000 after acquiring an additional 1,855,907 shares during the last quarter. Northern Trust Corp acquired a new position in Tonix Pharmaceuticals during the 4th quarter worth $162,000. PFG Investments LLC bought a new position in Tonix Pharmaceuticals in the 4th quarter valued at $72,000. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at $40,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TNXP has been the topic of several research reports. Wall Street Zen raised Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Noble Financial restated an "outperform" rating and set a $70.00 target price on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th.

Insiders Place Their Bets

In other news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was purchased at an average price of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the acquisition, the chief executive officer now owns 4,005 shares in the company, valued at $86,307.75. This trade represents a 80,000.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.03% of the company's stock.

Tonix Pharmaceuticals Trading Down 5.3%

TNXP traded down $2.22 during trading on Friday, reaching $39.80. 1,571,151 shares of the company's stock were exchanged, compared to its average volume of 888,377. The company's fifty day moving average price is $21.30 and its 200-day moving average price is $21.96. The firm has a market capitalization of $291.54 million, a PE ratio of -0.01 and a beta of 1.63. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $6.76 and a fifty-two week high of $558.08. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.23) by $0.39. The business had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.